Philips expands commercial availability of world’s first real-time AI-enabled light-based 3D navigation solution for image-guided therapy

Rhea-AI Summary

Philips (NYSE: PHG) announced expanded commercial availability of LumiGuide, the first real-time AI-enabled, light-based 3D navigation solution for image-guided therapy, across Europe and the United States, with commercial orders starting January 2026. LumiGuide uses Fiber Optic RealShape (FORS) to visualize guidewires and compatible catheters in 3D without continuous X-ray and integrates with the Azurion image-guided therapy platform. Philips cites clinical use in >2,000 procedures and a referenced single-center study reporting procedures up to 37% faster and up to 56% DAP reduction. LumiGuide has FDA clearance and CE marking.

Positive

• Commercial launch planned for January 2026
• Cited 37% faster procedure times in cited study
• Reported up to 56% DAP radiation reduction in cited study
• Used in >2,000 clinical procedures to date
• Integrates with Azurion platform treating >6.4M patients/year

Negative

• Some procedures may still require limited X-ray for initial anatomy
• Full commercial availability begins January 2026, following limited release

News Market Reaction

+0.57%

1 alert

+0.57% News Effect

On the day this news was published, PHG gained 0.57%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Procedure time reduction: 37% faster Radiation dose reduction: 56% DAP reduction Physician experience: Over 160 procedures +5 more

8 metrics

Procedure time reduction 37% faster Complex aortic repair procedures using LumiGuide FORS guidance

Radiation dose reduction 56% DAP reduction Single-center study of complex endovascular aortic repair

Physician experience Over 160 procedures Fenestrated and branched aortic procedures by cited vascular surgeon

Clinical use volume More than 2,000 procedures LumiGuide cases performed on Azurion platform

Patients treated on Azurion 6.4 million patients per year Azurion platform usage across over 80 countries

Global footprint More than 80 countries Azurion image-guided therapy platform deployment

Commercial availability date January 2026 LumiGuide commercial orders in Europe and United States

MRI field strength 3.0T BlueSeal Horizon MRI platform magnet strength

Market Reality Check

Price: $29.40 Vol: Volume 782,772 vs 20-day ...

normal vol

$29.40 Last Close

Volume Volume 782,772 vs 20-day average 642,234, indicating somewhat elevated trading interest ahead of this news. normal

Technical Shares at $27.01 are trading above the 200-day MA of $25.72 and about 8.56% below the 52-week high of $29.54.

Peers on Argus

Peers in Medical Devices showed mixed moves: DXCM +1.41%, while STE -3.43%, PODD...

Peers in Medical Devices showed mixed moves: DXCM +1.41%, while STE -3.43%, PODD -0.77%, ZBH -0.59%, SNN -1.03%. With PHG up 0.71%, this points to stock-specific rather than broad sector momentum.

Historical Context

5 past events · Latest: Dec 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 04	Outlook reiteration	Positive	-4.9%	Reiterated 2026 outlook with expected sales growth and margin expansion.
Dec 01	AI device rollout	Positive	+0.6%	Expanded LumiGuide AI 3D navigation availability across Europe and the US.
Nov 24	Imaging software launch	Positive	+0.4%	Launched web-based diagnostic viewer Philips Image Management 15 in the USA.
Nov 19	AI partnership	Positive	-1.6%	Extended Cortechs.ai partnership to integrate NeuroQuant into MR workflows.
Nov 17	AI procedure assist	Positive	-2.4%	Introduced DeviceGuide AI tracking to assist mitral valve repair procedures.

Pattern Detected

Recent Philips news, often positive on innovation and outlook, has more frequently seen share price weakness or only modest gains, suggesting a tendency toward muted or negative reactions even on constructive headlines.

Recent Company History

Over the last months, Philips has issued several innovation-focused and outlook-related updates. On Nov 17, it introduced AI-based DeviceGuide for mitral valve repair, followed by multiple AI and imaging launches and partnerships through Nov–Dec 2025. An outlook reiteration on Dec 04 highlighted expectations for sequential sales growth and margin expansion. Price reactions ranged from a -4.92% decline to small gains under 1%, indicating that investors have so far treated these developments cautiously. Today’s AI navigation expansion fits this ongoing innovation theme.

Market Pulse Summary

This announcement expands commercial availability of LumiGuide, an AI-enabled, light-based 3D naviga...

Analysis

This announcement expands commercial availability of LumiGuide, an AI-enabled, light-based 3D navigation solution integrated with the Azurion platform treating over 6.4 million patients annually in more than 80 countries. The cited data of up to 37% faster procedures and 56% DAP reduction highlights potential clinical and workflow benefits. In context of prior AI launches and partnerships, investors may focus on adoption rates from January 2026 onward and how these innovations translate into broader system demand and recurring usage.

Key Terms

endovascular, fluoroscopy, Fiber Optic RealShape (FORS), dose area product, +4 more

8 terms

endovascular medical

"improving navigation in complex endovascular procedures"

Endovascular describes medical procedures performed inside blood vessels using thin tubes, wires, and implantable devices guided by imaging—like repairing a broken pipe from the inside rather than opening the wall. It matters to investors because these less-invasive techniques can shorten hospital stays, lower complication rates and create demand for specialized devices and imaging equipment, so changes in adoption, regulation or reimbursement can materially affect healthcare company revenues and margins.

fluoroscopy medical

"reduces time on the fluoroscopy pedal to near zero"

Fluoroscopy is a medical imaging method that creates live X‑ray “video” of the inside of the body, allowing doctors to watch organs, bones, and instruments move during procedures, like viewing a real‑time map while driving. Investors care because fluoroscopy drives demand for imaging equipment, disposable supplies and procedure-related services, influences regulatory approvals and reimbursement rates, and affects clinical adoption that can shape revenues and costs in healthcare companies.

Fiber Optic RealShape (FORS) technical

"LumiGuide, powered by Philips Fiber Optic RealShape (FORS) technology"

Fiber Optic RealShape (FORS) is a medical imaging technology that uses light carried through thin optical fibers inside medical tools to create a live, three‑dimensional map of their position and shape inside the body. For investors, FORS matters because it can make minimally invasive procedures faster and safer—like turning a dim flashlight into a real‑time GPS for surgeons—potentially reducing X‑ray use, shortening procedures, and creating a market for related devices and software.

dose area product medical

"procedures can be performed 37% faster and with up to 56% DAP reduction"

Dose area product measures the total amount of radiation delivered during an X-ray or fluoroscopy procedure by combining how strong the beam is with how large an area it covers — think of it like the amount of paint applied across the whole wall rather than paint thickness alone. Investors care because it affects patient safety, regulatory compliance, device design and market acceptance; lower or better-controlled values can reduce liability, operating costs and help sell equipment.

FDA clearance regulatory

"LumiGuide has FDA clearance and CE marking"

FDA clearance is the U.S. Food and Drug Administration’s official permission to market certain medical devices or diagnostic tests after reviewing evidence that they are as safe and effective as similar products already on the market. For investors, it’s like a product passing a required safety inspection — it reduces regulatory uncertainty, speeds commercial rollout, and can directly affect sales prospects, valuation, and partnership opportunities.

CE marking regulatory

"LumiGuide has FDA clearance and CE marking"

CE marking is a symbol placed on certain products showing they meet European Union safety, health and environmental rules required to sell them in the EU/EEA. For investors, it signals that a product has cleared a common regulatory hurdle—like a passport for market access—reducing legal and market-entry risk and often widening sales opportunities across European markets.

image-guided therapy medical

"solution for image-guided therapy, across Europe and the United States"

Image-guided therapy uses real-time medical images—like X-rays, CT, MRI or ultrasound—to steer treatments, procedures or device placement so clinicians can see what they are doing inside the body. For investors, it matters because these technologies can improve treatment accuracy, shorten procedures, reduce complications and create demand for specialized devices and software, which can drive revenue growth and influence regulatory and reimbursement outcomes.

3.0T MRI medical

"BlueSeal Horizon [3], a new 3.0T MRI platform featuring the world’s first helium-free"

A 3.0T MRI is a medical imaging machine that uses a strong 3.0-tesla magnetic field—about 60,000 times stronger than Earth’s magnetic field—to create highly detailed pictures of organs, tissues and the brain. For investors, it matters because higher-field scanners typically offer clearer images and faster scans that can improve diagnostic accuracy, attract referrals, support advanced procedures, and command higher prices, but they also carry higher purchase, siting and maintenance costs.

AI-generated analysis. Not financial advice.

December 1, 2025

• Commercial availability expanded across Europe and the United States
• Real-time AI-enabled 3D device visualization powered by light instead of X-ray, improving navigation in complex endovascular procedures
• LumiGuide seamlessly integrates with Azurion, Philips’ proven, world-leading image-guided therapy platform designed to drive procedural innovation across clinical domains
  
  

Amsterdam, the Netherlands and Chicago, USA – Royal Philips (NYSE: PHG, AEX: PHIA, a global leader in health technology, today announced the expanded commercial availability of LumiGuide 3D Device Guidance, the world’s first real-time AI-enabled light-based 3D navigation solution for image-guided therapy, across Europe and the United States. LumiGuide represents a breakthrough in radiation-free* navigation, allowing physicians to visualize and guide devices inside the body using light instead of continuous X-ray. Announced at RSNA 2025, the wider commercial rollout marks the next step in Philips’ long-term commitment to improving radiation safety and dose reduction in image-guided therapy.

LumiGuide seamlessly integrates with Azurion, Philips’ proven, world-leading image-guided therapy platform designed to drive procedural innovation across clinical domains. Focused on improving outcomes, efficiency, and safety, LumiGuide joins a growing suite of intelligent, AI-enabled supportive and therapeutic devices integrated on the Azurion platform – a portfolio that spans both guidance technologies and therapeutic tools – redefining how clinicians plan, guide, and perform complex procedures with greater precision and confidence.

“I have done over 160 fenestrated and branched aortic procedures with LumiGuide and have found that the system improves efficiency, reduces the procedure time, and reduces time on the fluoroscopy pedal to near zero,” said Adam W. Beck, MD, Professor and Director, Division of Vascular Surgery & Endovascular Therapy, University of Alabama at Birmingham, US.

Transforming navigation inside the body – with light instead of X-ray
LumiGuide, powered by Philips Fiber Optic RealShape (FORS) technology, is the first solution to use light to visualize the shape and position of LumiGuide wires and compatible endovascular catheters inside the body in real time and in 3D – without X-ray. By reflecting light along an optical fiber integrated into the guidewire, LumiGuide shows high-resolution, full-color images from any angle, giving physicians instant orientation during complex endovascular procedures. LumiGuide uses AI to quickly and accurately align any image with the patient's anatomy. This technology allows clinicians to navigate with precision, while significantly reducing radiation exposure for both patients and clinical staff. Using this advanced technology, complex cases such as aortic repair procedures can be performed 37% faster and with up to 56% DAP reduction [1].

“Moving LumiGuide from limited to full commercial availability is an important milestone in expanding access to advanced image-guided therapy,” said Stacey Beske, Business Leader Image-Guided Therapy Devices at Philips.

“By bringing this light-based navigation technology to more hospitals, we’re helping clinicians treat complex vascular disease with precision and safety, while reducing radiation risk for patients and teams in the lab,” added Atul Gupta, MD, Chief Medical Officer Diagnosis & Treatment at Philips.

Proven Azurion platform
LumiGuide is the latest innovation built on Philips leadership in Image Guided Therapy and the proven Azurion platform – the foundation for procedural innovation across clinical domains. Seamlessly integrated into Azurion, LumiGuide demonstrates how Philips continues to advance minimally invasive therapies through integration of intelligent systems and devices that combine real-time insight, precision navigation, and procedural efficiency. Built on a platform that treats over 6.4 million patients each year across more than 80 countries [2], with high-quality, low-dose imaging and enhanced workflow efficiency, LumiGuide extends Philips’ commitment to making image-guided therapy safer, faster, and more effective for patients and clinical teams. Together with AI-enabled innovations such as DeviceGuide and VeriSight 3D ICE, Philips is integrating intelligence and imaging to enable the next generation of procedural precision and confidence, all within the connected Azurion environment.

Accelerating access and adoption
Following a successful limited market release in late 2023, LumiGuide will be commercially available from January 2026 in key European markets and the United States** Over the past years, LumiGuide has been used in more than 2,000 clinical procedures [2], integrated with Philips Azurion image-guided therapy platform. Building on this experience, Philips continues to invest in clinical evidence generation to help clinicians optimize the use of LumiGuide in everyday practice.

Advancing radiation safety in image-guided therapy
LumiGuide builds on Philips’ broader portfolio of innovations aimed at reducing or eliminating radiation exposure during image-guided procedures. Alongside technologies such as Azurion with ClarityIQ, DoseAware, and EchoNavigator, and complementary clinical programs like the RADIQAL trial, LumiGuide underscores Philips’ leadership in low- and no-dose interventional solutions, helping to make image-guided therapy safer, more efficient, and more sustainable.

Learn more
To learn more about Philips LumiGuide and its integration within Philips Image Guided Therapy portfolio, visit www.philips.com/lumiguide.


Also unveiled at RSNA is BlueSeal Horizon [3], a new 3.0T MRI platform featuring the world’s first helium-free 3.0T magnet and next-generation AI designed to enhance workflow efficiency and diagnostic precision.

[1] Eric J. Finnesgard, Jessica P. Simons, Douglas W. Jones, Caitlin M. Sorensen, Tammy T. Nguyen, Andres Schanzer. Initial single-center experience using Fiber Optic RealShape guidance in complex endovascular aortic repair, Journal of Vascular Surgery, November 12, 2022. https://doi.org/10.1016/j.jvs.2022.11.041.
[2] Data on file at Philips.
[3] 3.0T BlueSeal Horizon is ‘Work in Progress’ and not available in any jurisdiction. It is not for sale in the USA. Its future availability cannot be ensured. 

*While navigation with LumiGuide itself involves no radiation exposure, some clinical procedures may incorporate limited X-ray imaging for initial anatomical visualization.
** LumiGuide has FDA clearance and CE marking and will be commercially available for order in the United States and Europe starting January 2026.
*** The opinions and clinical experiences presented herein are specific to the featured topic(s), are not linked to any specific patient and are for information purposes only. The medical experience(s) derived from these topics may not be predictive of all patients.  Individual results may vary depending on a variety of patient-specific attributes and related factors.  Nothing in this presentation is intended to provide specific medical advice or to take the place of written law or regulations.

For further information, please contact:

Joost Maltha
Philips Global External Relations
Tel.: +31 6 1055816
E-mail: joost.maltha@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

• Philips LumiGuide 3D device guidance in use

FAQ

When will Philips (PHG) make LumiGuide commercially available in the US and Europe?

LumiGuide will be commercially available for order in the United States and key European markets starting January 2026.

What clinical benefits did Philips report for LumiGuide in the referenced study?

A cited single-center study reported complex cases performed up to 37% faster with up to 56% DAP radiation reduction.

Does LumiGuide eliminate radiation exposure during image-guided procedures (PHG)?

LumiGuide navigation itself involves no radiation, but some procedures may still use limited X-ray for initial anatomical visualization.

Is LumiGuide cleared by regulators for commercial use (PHG)?

Yes; LumiGuide has received both FDA clearance and CE marking.

How widely has LumiGuide been used clinically before full rollout (PHG)?

Philips reports LumiGuide has been used in more than 2,000 clinical procedures during limited release and integration with Azurion.